Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

A North Texas woman with a cautionary tale warns others to do their research before starting popular weight loss drugs.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Trump signs executive order, discussed "overweight" friend who was taking the "fat shot drug." It wasn't confirmed whether he meant Ozempic or Wegovy.